{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T06:37:25Z","timestamp":1790059045948,"version":"4.0.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T00:00:00Z","timestamp":1601078400000},"content-version":"vor","delay-in-days":4378,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Lipid Research"],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1194\/jlr.m800082-jlr200","type":"journal-article","created":{"date-parts":[[2008,6,3]],"date-time":"2008-06-03T01:19:21Z","timestamp":1212455961000},"page":"2142-2148","source":"Crossref","is-referenced-by-count":58,"title":["Induction of paraoxonase 1 and apolipoprotein A-I gene expression by aspirin"],"prefix":"10.1016","volume":"49","author":[{"given":"Priscilla","family":"Jaichander","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krithika","family":"Selvarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahdi","family":"Garelnabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sampath","family":"Parthasarathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1194\/jlr.M800082-JLR200_bib1","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1194\/jlr.M400213-JLR200","article-title":"Purified human serum PON1 does not protect LDL against oxidation in the in vitro assays initiated with copper or AAPH","volume":"45","author":"Teiber","year":"2004","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.M800082-JLR200_bib2","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0006-2952(03)00401-5","article-title":"Lactonase and lactonizing activities of human serum paraoxonase (PON1) and rabbit serum PON3","volume":"66","author":"Teiber","year":"2003","journal-title":"Biochem. Pharmacol."},{"key":"10.1194\/jlr.M800082-JLR200_bib3","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.1074\/jbc.275.6.3957","article-title":"Calcium-dependent human serum homocysteine thiolactone hydrolase. A protective mechanism against protein N-homocysteinylation","volume":"275","author":"Jakubowski","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1194\/jlr.M800082-JLR200_bib4","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.freeradbiomed.2005.03.016","article-title":"Paraoxonases (PONs) 1, 2, and 3 are expressed in human and mouse gastrointestinal tract and in Caco-2 cell line: selective secretion of PON1 and PON2","volume":"39","author":"Shamir","year":"2005","journal-title":"Free Radic. Biol. Med."},{"key":"10.1194\/jlr.M800082-JLR200_bib5","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1161\/ATVBAHA.107.141747","article-title":"HDL oxidation compromises its influence on paraoxonase-1 secretion and its capacity to modulate enzyme activity","volume":"27","author":"Deakin","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"10.1194\/jlr.M800082-JLR200_bib6","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1172\/JCI1649","article-title":"Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase","volume":"101","author":"Aviram","year":"1998","journal-title":"J. Clin. Invest."},{"key":"10.1194\/jlr.M800082-JLR200_bib7","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.bbagen.2005.07.005","article-title":"Oxidative inactivation of paraoxonase\u2014implications in diabetes mellitus and atherosclerosis","volume":"1725","author":"Karabina","year":"2005","journal-title":"Biochim. Biophys. Acta."},{"key":"10.1194\/jlr.M800082-JLR200_bib8","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/28406","article-title":"Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis","volume":"394","author":"Shih","year":"1998","journal-title":"Nature."},{"key":"10.1194\/jlr.M800082-JLR200_bib9","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1161\/01.CIR.0000023623.87083.4F","article-title":"Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice","volume":"106","author":"Tward","year":"2002","journal-title":"Circulation."},{"key":"10.1194\/jlr.M800082-JLR200_bib10","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1161\/ATVBAHA.106.134189","article-title":"Adenovirus-mediated expression of human paraoxonase 3 protects against the progression of atherosclerosis in apolipoprotein E-deficient mice","volume":"27","author":"Ng","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1194\/jlr.M800082-JLR200_bib11","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/S0002-9149(02)02635-8","article-title":"High-density lipoproteins and atherosclerosis","volume":"90","author":"Rader","year":"2002","journal-title":"Am. J. Cardiol."},{"key":"10.1194\/jlr.M800082-JLR200_bib12","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1161\/01.RES.0000185320.82962.F7","article-title":"Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation","volume":"97","author":"Moore","year":"2005","journal-title":"Circ. Res."},{"key":"10.1194\/jlr.M800082-JLR200_bib13","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1093\/carcin\/22.8.1111","article-title":"A reappraisal of the potential chemopreventive and chemotherapeutic properties of resveratrol","volume":"22","author":"Gusman","year":"2001","journal-title":"Carcinogenesis."},{"key":"10.1194\/jlr.M800082-JLR200_bib14","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1096\/fj.03-0168rev","article-title":"Resveratrol: from grapevines to mammalian biology","volume":"17","author":"Pervaiz","year":"2003","journal-title":"FASEB J."},{"key":"10.1194\/jlr.M800082-JLR200_bib15","doi-asserted-by":"crossref","first-page":"5209","DOI":"10.1128\/MCB.24.12.5209-5222.2004","article-title":"Dietary polyphenols increase paraoxonase 1 gene expression by an aryl hydrocarbon receptor-dependent mechanism","volume":"24","author":"Gouedard","year":"2004","journal-title":"Mol. Cell. Biol."},{"key":"10.1194\/jlr.M800082-JLR200_bib16","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1042\/bj3400715","article-title":"Dietary flavonols quercetin and kaempferol are ligands of the aryl hydrocarbon receptor that affect CYP1A-I transcription differentially","volume":"340","author":"Ciolino","year":"1999","journal-title":"Biochem. J."},{"key":"10.1194\/jlr.M800082-JLR200_bib17","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0049-3848(03)00379-7","article-title":"The mechanism of action of aspirin","volume":"110","author":"Vane","year":"2003","journal-title":"Thromb. Res."},{"key":"10.1194\/jlr.M800082-JLR200_bib18","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1055\/s-2003-40668","article-title":"Aspirin and other cyclooxygenase inhibitors: new therapeutic insights","volume":"3","author":"Wu","year":"2003","journal-title":"Semin. Vasc. Med."},{"key":"10.1194\/jlr.M800082-JLR200_bib19","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/newbio231232a0","article-title":"Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs","volume":"231","author":"Vane","year":"1971","journal-title":"Nat. New Biol."},{"key":"10.1194\/jlr.M800082-JLR200_bib20","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1111\/j.1538-7836.2004.00806.x","article-title":"Aspirin and platelet function","volume":"2","author":"Breddin","year":"2004","journal-title":"J. Thromb. Haemost."},{"key":"10.1194\/jlr.M800082-JLR200_bib21","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.atherosclerosis.2004.10.047","article-title":"Stabilization of advanced atherosclerosis in low-density lipoprotein receptor-deficient mice by aspirin","volume":"184","author":"Cyrus","year":"2006","journal-title":"Atherosclerosis."},{"key":"10.1194\/jlr.M800082-JLR200_bib22","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/BF01073867","article-title":"The pharmacokinetics of aspirin in rats and the effect of buffer","volume":"19","author":"Fu","year":"1991","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"10.1194\/jlr.M800082-JLR200_bib23","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1600-0773.1982.tb01028.x","article-title":"Systemic availability of acetylsalicylic acid in human subjects after oral ingestion of three different formulations","volume":"51","author":"Petersen","year":"1982","journal-title":"Acta Pharmacol. Toxicol. (Copenh.)."},{"key":"10.1194\/jlr.M800082-JLR200_bib24","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.atherosclerosis.2006.05.027","article-title":"Aspirin is a substrate for paraoxonase-like activity: implications in atherosclerosis","volume":"191","author":"Santanam","year":"2007","journal-title":"Atherosclerosis."},{"key":"10.1194\/jlr.M800082-JLR200_bib25","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1124\/mol.63.4.945","article-title":"Opposite regulation of the human paraoxonase-1 gene PON-1 by fenofibrate and statins","volume":"63","author":"Gouedard","year":"2003","journal-title":"Mol. Pharmacol."},{"key":"10.1194\/jlr.M800082-JLR200_bib26","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1161\/01.ATV.15.11.1812","article-title":"Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins","volume":"15","author":"Abbott","year":"1995","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1194\/jlr.M800082-JLR200_bib27","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S0888-7543(05)80133-8","article-title":"Characterization of the mouse apolipoprotein Apoa-1\/Apoc-3 gene locus: genomic, mRNA, and protein sequences with comparisons to other species","volume":"14","author":"Januzzi","year":"1992","journal-title":"Genomics."},{"key":"10.1194\/jlr.M800082-JLR200_bib28","doi-asserted-by":"crossref","first-page":"25713","DOI":"10.1074\/jbc.273.40.25713","article-title":"The nuclear receptors peroxisome proliferator-activated receptor alpha and Rev-erb alpha mediate the species-specific regulation of apolipoprotein A-I expression by fibrates","volume":"273","author":"Vu-Dac","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1194\/jlr.M800082-JLR200_bib29","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S0022-2275(20)31485-1","article-title":"Dietary oxidized fatty acids may enhance intestinal apolipoprotein A-I production","volume":"43","author":"Rong","year":"2002","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.M800082-JLR200_bib30","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1126\/science.8052854","article-title":"Inhibition of NF-kappa B by sodium salicylate and aspirin","volume":"265","author":"Kopp","year":"1994","journal-title":"Science."},{"key":"10.1194\/jlr.M800082-JLR200_bib31","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0022-2275(20)33887-6","article-title":"Human S mu binding protein-2 binds to the drug response element and transactivates the human apoA-I promoter: role of gemfibrozil","volume":"39","author":"Mohan","year":"1998","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.M800082-JLR200_bib32","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.tox.2005.07.020","article-title":"PPAR alpha activation potentiates AhR-induced CYP1A-I expression","volume":"216","author":"Fallone","year":"2005","journal-title":"Toxicology."},{"key":"10.1194\/jlr.M800082-JLR200_bib33","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nrd794","article-title":"Potential cardioprotective actions of no-releasing aspirin","volume":"5","author":"Wallace","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1194\/jlr.M800082-JLR200_bib34","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00125-003-1065-0","article-title":"Aspirin use is associated with higher serum concentrations of the anti-oxidant enzyme, paraoxonase-1","volume":"46","author":"Blatter-Garin","year":"2003","journal-title":"Diabetologia."}],"container-title":["Journal of Lipid Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002222752034637X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002222752034637X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1194\/jlr.M800082-JLR200","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,20]],"date-time":"2021-11-20T18:27:48Z","timestamp":1637432868000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002222752034637X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["S002222752034637X"],"URL":"https:\/\/doi.org\/10.1194\/jlr.m800082-jlr200","relation":{},"ISSN":["0022-2275"],"issn-type":[{"value":"0022-2275","type":"print"}],"subject":[],"published":{"date-parts":[[2008,10]]}}}